Indications
Melatonin Neurim is indicated as monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.
Composition
- Active substance
- melatonin
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Melatonin Neurim
- Active substance
- melatonin
- ATC code
- N05CH01
- Group
- Nervous system
- Therapeutic area
- Sleep Initiation and Maintenance Disorders
- Marketing authorisation holder
- RAD Neurim Pharmaceuticals EEC SARL
- Status
- Authorised
- EU authorisation